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Background: The perioperative management of antiplatelet therapy in noncardiac surgery patients who have undergone
previous percutaneous coronary intervention (PCI) remains a dilemma. Continuing dual antiplatelet therapy (DAPT) may
carry a risk of bleeding, while stopping antiplatelet therapy may increase the risk of perioperative major adverse car-
diovascular events (MACE).
Methods: Occurrence of Bleeding and Thrombosis during Antiplatelet Therapy In Non-Cardiac Surgery (OBTAIN) was an
international prospectivemulticentre cohort study of perioperative antiplatelet treatment, MACE, and serious bleeding in
noncardiac surgery. The incidences of MACE and bleeding were compared in patients receiving DAPT, monotherapy, and
no antiplatelet therapy before surgery. Unadjusted risk ratios were calculated taking monotherapy as the baseline. The
adjusted risks of bleeding and MACE were compared in patients receiving monotherapy and DAPT using propensity score
matching.
Results: A total of 917 patients were recruited and 847 were eligible for inclusion. Ninety-six patients received no anti-
platelet therapy, 526 received monotherapy with aspirin, and 225 received DAPT. Thirty-two patients suffered MACE and
22 had bleeding. The unadjusted risk ratio for MACE in patients receiving DAPT compared with monotherapy was 1.9
(0.93e3.88), P¼0.08. There was no difference in MACE between no antiplatelet treatment and monotherapy 1.03 (0.31e
3.46), P¼0.96. Bleeding was more frequent with DAPT 6.55 (2.3e17.96) P¼0.0002. In a propensity matched analysis ofl decision: 24 September 2018; Accepted: 24 September 2018
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Perioperative antiplatelet therapy after PCI - 171177 patients who received DAPT and 177 monotherapy patients, the risk ratio for MACE with DAPT was 1.83 (0.69e4.85),
P¼0.32. The risk of bleeding was significantly greater in the DAPT group 4.00 (1.15e13.93), P¼0.031.
Conclusions: OBTAIN showed an increased risk of bleeding with DAPT and found no evidence for protective effects of
DAPT from perioperative MACE in patients who have undergone previous PCI.
Keywords: acetylsalicylic acid; antiplatelet therapy; bleeding; major adverse cardiovascular events; outcome; percuta-
neous coronary intervention; surgeryEditor’s key points
 There is only limited evidence that continuation of dual
antiplatelet therapy (DAPT) in patients undergoing
noncardiac surgery with previous percutaneous coro-
nary intervention is beneficial in the prevention of
major adverse cardiovascular events (MACE).
 The OBTAIN study suggests lack of protection by peri-
operative continuation of DAPT, while the risk of harm
from bleeding is increased.
 The findings from the OBTAIN study should, however,
be viewed in the light of its observational nature, the
small sample size, and the lack of long-term and
standardised monitoring of MACE.The optimal management of antiplatelet agents in patients
who have undergone recent percutaneous coronary interven-
tion (PCI) requiring noncardiac surgery remains a vexed issue.
Coronary stents are an effective technology for the prevention
of coronary artery restenosis after angioplasty, but until they
become covered by endothelium, however, the metal struts of
coronary stents offer an ideal surface for the formation of
thrombus.1 Endothelial coverage can take 3 months for bare
metal stents (BMS) and longer for drug eluting stents (DES), and
late stent thrombosis may occur for up to 4 yr after PCI.2,3
Dual antiplatelet therapy (DAPT) with aspirin and a platelet
P2Y12 receptor blocker is commonly used to prevent stent
thrombosis. It is recommended that DAPT be administered for
at least 1 month after BMS implantation in stable coronary
artery disease, for 6 months after new-generation DES im-
plantation, and for up to 1 yr in patients after acute coronary
syndrome, irrespective of revascularisation strategy.4,5 After
the introduction of coronary stents, mortality rates of up to
20% were reported in patients in whom antiplatelet agents
were discontinued and noncardiac surgery performed in the
first 2 months after PCI.6 However, because of the increased
risk of bleeding, it is preferable to avoid continuation of DAPT
during surgery.7 Surgery is the second common cause for
withdrawal of antiplatelet therapy within 6 months of PCI and
themost common cause of withdrawal between 6months and
1 yr after PCI.8e11
The British National Formulary recommends withdrawing
clopidogrel 7 days before surgery if an antiplatelet effect is not
desirable.12 There remains substantial uncertainty and limited
evidence as to whether patients who undergo noncardiac
surgery within 3 months of the placement of a BMS or 12
months of a DES should receive aspirin alone or DAPT
throughout the perioperative period. The present study aimed
to prospectively investigate antiplatelet use and the occur-
rence of major adverse cardiovascular events (MACE) andbleeding in patients who underwent noncardiac surgery
within 4 yr of PCI.Methods
The prospective cohort study ‘Occurrence of Bleeding and
Thrombosis during Antiplatelet Therapy In Non-Cardiac Sur-
gery’ (OBTAIN) included patients requiring elective or urgent
noncardiac surgery who had undergone PCI in the preceding 4
yr. Urgent surgery was defined as surgery with a time from the
decision to operate to surgery of at least 7 days (i.e. a sufficient
interval to modify antiplatelet therapy). Patients requiring
emergency surgery were excluded. Patients were approached
either in the pre-assessment clinic or upon admission for
surgery depending on local arrangements. The study was
approved by Research Ethics Committees in each national
jurisdiction and consent gained from patients at the time of
enrolment. Details of national research ethics approvals are
held by the European Society of Anaesthesiology Clinical Tri-
als Network (ESA-CTN) Office.
The management of antiplatelet therapy through the
perioperative period was at the discretion of the clinical
teams. Data were collected on cardiovascular risk factors,
antiplatelet agent management, MACE, and bleeding events.
The occurrence of MACE and bleeding were compared in pa-
tients who received dual, single, or no antiplatelet therapy in
the perioperative period.
Preoperative data collected included details of the most
recent PCI (dateof PCI, numberof stents deployed, typeof stents
used), risk factors for stent thrombosis (age>79 yr, impaired left
ventricular function, stent placed for acute coronary syndrome,
multiple stents, diabetes, renal impairment), historyofprevious
cardiovascular morbidity [myocardial infarction (MI), cerebro-
vascular accident (CVA), heart failure, angina), other perioper-
ative cardiovascular risk factors (left ventricular hypertrophy,
limited exercise tolerance, history of smoking), cardiovascular
medication use, and risk factors for bleeding.4,13,14 Operations
were classified as low-, intermediate-, and high-risk groups,
with estimated 30-day cardiac event rates of <1%, 1e5%, and
>5%, respectively, as described in the 2009 European guidelines
on preoperative cardiac risk assessment and perioperative
cardiac management in noncardiac surgery.15
The effect of variation in the use of DAPT by country was
included in the analysis. Countries were classified depending
on whether their overall rate of use of dual therapy (as
opposed to monotherapy) was <25%, 25e50%, or >50%
(Table 1). This allowed us to take account of the observed
differences in national practice whilst matching on three
categories rather than at an individual country level.
Patients were considered to have discontinued aspirin,
clopidogrel, or prasugrel before surgery if they stopped taking
Table 1 Participating countries classified into three groups
according the percentage of patients who underwent surgery
whilst receiving dual antiplatelet therapy. DAPT, dual anti-
platelet therapy
Group 1
perioperative
DAPT <25%
Group 2
perioperative
DAPT 25e50%
Group 3
perioperative
DAPT >50%
France Belgium Greece
The Netherlands Portugal Germany
UK Spain Lithuania
Romania
Turkey
Kosovo
172 - Howell et al.the agent 7 days before operation.12 Monotherapy was
considered to be treatment with aspirin alone, and dual ther-
apy was treatment with aspirin and either clopidogrel or
prasugrel. MACE that were detected as part of routine care
were recorded. Additional surveillance with ECGs or cardiac
biomarker assays was not performed as part of the study.
Patients were considered to have suffered a major adverse
event if they suffered an MI as defined by the Universal Defi-
nition of Myocardial Infarction (including cardiac arrest and
cardiac death as described in this definition) or PCI for a car-
diac event occurring after surgery.16 Major perioperative
bleeding events were considered to be reoperation for
bleeding, gastrointestinal haemorrhage, intracranial haemor-
rhage, haemorrhagic stroke, spinal, or epidural haematoma.
These outcomes were selected to be robust endpoints
confirmed by investigation or intervention (reoperation,
endoscopy, CT scan, or MRI scan) and to avoid subjective
judgements, for example regarding the size and importance of
a wound haematoma. Events were adjudicated within the
local centre and discussed with the lead national investigator
in cases of uncertainty. Blood transfusion was not included
within the definition ofmajor bleeding, as transfusion practice
varies widely across different centres.17,18Statistical analysis
Thestatistical softwareusedwasR (https://www.R-project.org/)
with the MatchIt package.19 A simple unadjusted comparison
of the incidence ofMACE and bleeding events between patients
receiving DAPT, single antiplatelet therapy, and no antiplatelet
therapy through the perioperative period was made using
Pearson’s c2 test. In addition, unadjusted relative risk ratios for
bleeding and MACE were calculated taking the group who
received monotherapy (aspirin alone) as the baseline group.
An important concern in this study was confounding by
indication (i.e. bias as a result of those patients receiving dual
therapy being at higher risk of MACE). Confounding was
addressed by propensity scorematching on variables shown to
predict receipt of dual therapy as opposed to monotherapy.
Logistic regressionwas used to identify factors associated with
the propensity for dual therapy rather than monotherapy. The
clustering of patients within centres was accounted for by
fitting a random intercept for centre. The random intercept
was to be dropped from the model if a lower Akaike’s Infor-
mation Criterion (AIC) was achieved without accounting for
clustering: that is if clustering was seen to not improve the
propensity model sufficiently. All subsets of factors in thepropensity model were explored and the selected model had
the lowest AIC with all factors providing a statistically signif-
icant association between the factor and the propensity for
dual therapy. Propensity score matching was used to select
two groups for comparison: those on monotherapy and those
on dual therapy. Matching was performed using 1:1 nearest
neighbour matching. Direct comparisons were undertaken
between the two matched groups. Standardised differences of
relevant clinical characteristics between the two groups are
reported. There were too few events in the group of patients
receiving no antiplatelet therapy to support a propensity
matched analysis that included this subgroup of patients.
Power calculations were performed for both bleeding and
MACE outcomes using the ‘sampsi’ function of State SE 9, Sta-
taCorp, College Station, TX, USA. Both calculations were based
ona type1 error of 0.05andapowerof 0.8. ForMACE, the studies
of Nuttall and colleagues20 and Rabbitts and colleagues21 sug-
gest that the risk of perioperative MACE in a similar population
is 5%. We assumed a doubling in the incidence of MACE if clo-
pidogrel is discontinued (Iakovouandcolleagues4 reported a 90-
fold increased risk of stent thrombosis if antiplatelet agents
were discontinued in medical patients). Based on a discontin-
uation rate of 50% we calculated that 474 patients would be
required in the mono and DAPT groups; a total of 948 patients.
There were few data from large studies on the association be-
tween clopidogrel and perioperative bleeding in noncardiac
surgery. Whilst carried out in cardiac surgery, the study of
Kapetanakis and colleagues22which included 2359 patients and
used robust definitions for bleeding outcomes was the best
available evidence on which to base a power calculation.
Kapetanakis and colleagues22 reported a baseline incidence of
1.3% for reoperation for bleeding in cardiac surgery, rising to
5.8% for patients receiving clopidogrel. The adjusted odds ratio
for bleeding associated with clopidogrel was 5.7 (1.81e18.15).
For the purposes of this power calculation, we assumed a 1%
baseline incidence of clinically significant bleeding and a rela-
tive risk of bleeding associated with clopidogrel of 4.0. Using
these assumptions we calculated that 489 patients would be
required in each group; a total of 978 patients. In order to allow
fora 10% loss for follow-upandtoallowfor thedevelopmentofa
robust propensity score model we aimed to recruit 1400 pa-
tients.Wewereawareof the limitationsof thesecalculations for
an observational study. In particular, we could not be sure of a
balance between the mono and DAPT groups.Results
Nine hundred and seventeen patients from 41 centres in 12
countries were enrolled into the study between March 2011
and December 2013. The Steering Group made the decision to
close the study after 917 patients had been recruited, because
an interim analysis had shown a statistically significant as-
sociation between dual antiplatelet therapy and bleeding.
There was a higher incidence of MACE in the DAPT group than
in the monotherapy group (the opposite direction to what had
been expected).
Of the 917 patients recruited, 847 were eligible for inclusion
(Fig. 1). Thirty-eight patients were excluded as they had un-
dergone PCI more than 4 yr before noncardiac surgery. In 31
excluded patients, PCI and surgery were planned together,
meaning that decisions regarding antiplatelet therapy for
noncardiac surgery were made at the time of PCI and the PCI
strategy may have been modified with noncardiac surgery in
view. One patient who received bridging anticoagulant
917 Paents enrolled 
847 Included in univariate analysis 
751 Received single or dual 
anplatelet therapy
628 Propensity matching 
354 Successfully matched 
70 Excluded 
96 Received no anplatelet therapy 
Insuﬃcient events for mulvariate 
modelling 
123 Because of missing values for 
propensity model covariates 
12 Dual therapy paents discarded 
as no good match could be found. 
262 Monotherapy paents 
unmatched. 
Fig 1. CONSORT flow diagram of recruitment of patients into Occurrence of Bleeding and Thrombosis during Antiplatelet Therapy in Non-
Cardiac Surgery (OBTAIN).
Perioperative antiplatelet therapy after PCI - 173therapy after the withdrawal of antiplatelet therapy was
excluded. Differences in the use of perioperative DAPT were
noted between different counties, as reported in Table 1.
Ninety-six patients received no antiplatelet therapy in the
perioperative period, 526 received monotherapy with aspirin
alone, and 225 received DAPTwith aspirin and clopidogrel (194
patients) or prasugrel (31 patients). The clinical characteristics
of these three groups of patients are reported in Table 2.
Thirty-two patients experienced MACE; three in the group
who received no antiplatelet therapy, 16 in the monotherapy
group, and 13 in the group who received DAPT. Of these, 28
patients suffered a perioperative cardiac event that fulfilledthe 2007 universal definition of MI criteria, six patients un-
derwent acute postoperative PCI (including two who were
defined as having suffered an MI by the 2007 criteria), and one
patient suffered a fatal postoperative MI. Twenty-two patients
experienced clinically significant bleeding events; three of
these patients received no antiplatelet therapy in the periop-
erative period, five received monotherapy, and 14 received
DAPT. Eighteen patients underwent reoperation for bleeding,
three patients suffered a postoperative gastrointestinal bleed,
and one patient developed an epidural haematoma. As noted
above, one patient died after a postoperative MI. No other
deaths were reported.
Table 2 Patient characteristics. (Some percentages do not add up to exactly 100% because of rounding.) CVA, cerebrovascular accident;
MI, myocardial infarction; PCI percutaneous coronary intervention
Factor No aspirin, n (%) Monotherapy, n (%) Dual-therapy, n (%) P-value
Subjects (number) 96 526 225
Sex Male 66 (68.8) 398 (75.7) 186 (82.7) 0.017
Female 30 (31.2) 128 (24.3) 39 (17.3)
Age (yr) 31e59 11 (11.5) 98 (18.6) 45 (20.0) 0.455
60e69 30 (31.2) 163 (31.0) 75 (33.3)
70e79 38 (39.6) 191 (36.3) 80 (35.6)
80e91 17 (17.7) 74 (14.1) 25 (11.1)
Country group <25% 63 (65.6) 347 (66.0) 91 (40.4) <0.001
25e50% 15 (15.6) 140 (26.6) 82 (36.4)
>50% 18 (18.8) 39 (7.4) 52 (23.1)
Smoking Never 33 (34.4) 175 (33.3) 73 (32.4) 0.194
Ex-smoker 43 (44.8) 247 (47.0) 95 (42.2)
Current 9 (9.4) 75 (14.3) 39 (17.3)
Not recorded 11 (11.5) 29 (5.5) 18 (8.0)
Able to climb stairs Able 62 (64.6) 356 (67.7) 140 (62.2) 0.698
Unable 21 (21.9) 106 (20.2) 52 (23.1)
Not recorded 13 (13.5) 64 (12.2) 33 (14.7)
Diabetes mellitus Diabetic 31 (32.3) 112 (21.3) 73 (32.4) 0.002
Non-diabetic 65 (67.7) 414 (78.7) 152 (67.5)
Urgency of PCI Elective 50 (52.1) 217 (41.3) 76 (33.8) 0.014
Acute 38 (39.6) 266 (50.6) 135 (60.0)
Not recorded 8 (8.3) 43 (8.2) 14 (6.2)
Time from PCI to surgery (days) 0e364 21 (21.9) 83 (15.8) 139 (61.8) <0.001
365e729 30 (31.2) 194 (36.9) 48 (21.3)
730e1459 45 (46.9) 249 (47.3) 38 (16.9)
Number of stents 0 or1 65 (67.7) 290 (55.1) 120 (53.3) 0.012
2þ 27 (28.1) 215 (40.9) 103 (45.8)
Unknown 4 (4.2) 21 (4.0) 2 (0.9)
Ejection fraction Good or not recorded 82 (84.4) 462 (87.8) 167 (74.2) 0.012
Impaired 14 (14.6) 64 (12.2) 58 (25.8)
Surgery Elective 95 (99.0) 517 (98.3) 211 (93.8) 0.002
Acute 1 (1.0) 9 (1.7) 14 (6.2)
Operation risk Low 47 (49.0) 259 (49.2) 97 (43.1) 0.079
Intermediate or high 49 (51.0) 267 (50.8) 128 (56.9)
ASA physical status 1 or 2 28 (29.2) 167 (31.7) 47 (20.9) 0.017
3 56 (58.3) 298 (56.7) 137 (60.9)
4 11 (11.5) 48 (9.1) 37 (16.4)
Not recorded 1 (1.0) 13 (2.5) 4 (1.8)
Previous MI Previous MI 33 (34.4) 159 (30.2) 88 (36.1) 0.058
No previous MI 63 (65.6) 367 (69.8) 137 (63.9)
Current angina Angina 42 (43.8) 229 (43.5) 96 (42.7) 0.972
No angina 54 (56.2) 297 (56.5) 129 (57.3)
History of heart failure Heart failure 5 (5.2) 20 (3.8) 18 (8.0) 0.056
No heart failure 91 (94.8) 506 (96.2) 207 (92.0)
Previous CVA Previous CVA 9 (9.4) 29 (5.5) 21 (9.3) 0.104
No previous CVA 87 (90.6) 497 (94.5) 204 (90.7)
Urgency of surgery Urgent 1 (1.0) 9 (1.7) 14 (6.2) 0.002
Non-urgent 95 (99.0) 517 (98.3) 211 (93.8)
174 - Howell et al.The occurrences of MACE and significant bleeding in pa-
tients on dual, single, and no antiplatelet therapy during the
perioperative period are shown in Table 3. Whilst the odds
ratio for MACE in the DAPT as compared with the mono-
therapy with aspirin was greater than unity, this was not
statistically significant with risk ratio (RR) 1.9 (0.93e3.88). The
risk of MACE was almost identical in patients receiving no
antiplatelet treatment and those receiving aspirin over the
perioperative period [1.03 (0.31e3.46)]. Bleeding was signifi-
cantly more frequent in patients on DAPT as compared with
patients on aspirin alone [6.55 (2.39e17.96)].
As noted above, these unadjusted results were potentially
affected by confounding by indication and we therefore un-
dertook a propensity score matching analysis. This analysiswas only possible for patients receiving single therapy or
DAPT. Ninety-six patients received no antiplatelet therapy in
the perioperative period. As this group experienced only three
MACE and three bleeding events, further analyses were not
performed and these patients were excluded from the pro-
pensity weighted analysis.
All variables listed in Table 2 were included in the logistic
regression modelling process. The final propensity score
model included the following covariates: country group, time
since PCI, ejection fraction, urgency of surgery, and previous
MI. One hundred and twenty-three patients were excluded
from the matching process because of missing or unavailable
data on covariates (e.g. data on ejection fraction was only
available in patients who had undergone echocardiography or
Table 3 Association between antiplatelet therapy, bleeding, and major adverse cardiovascular events (MACE); unadjusted analysis.
The percentage of MACE and bleeding events in each group is given in parenthesis. The overall P-value across the three groups for
MACE and bleeding are given in the final column. The odds ratios (OR) for MACE and bleeding are given taking themonotherapy group
as baseline
No perioperative antiplatelet therapy,
N¼96, n (%)
Mono-therapy,
N¼526, n (%)
Dual therapy, N¼225, n (%) Overall P-value
MACE 3 (3.1) OR 1.03 (0.31e3.46) P¼0.96 16 (3.0) 13 (5.8) OR 1.9 (0.93e3.88) P¼0.08 0.115
Bleeding 3 (3.1) OR 3.29 (0.80e13.53) P¼0.10 5 (1.0) 14 (6.2) OR 6.55 (2.39e17.96) P¼0.0002 <0.001
Perioperative antiplatelet therapy after PCI - 175other cardiac imaging). Six hundred and twenty eight patients
(439 monotherapy and 189 dual therapy) were selected for
propensity score matching. We matched at a ratio of 1:1 with
the nearest propensity scorematch, without replacement. The
use of a calliper was not found to be useful. Violin plots
demonstrated propensities ranging from zero to unity for the
monotherapy group, whereas for patients who received dual
therapy, propensities ranged from 0.2 to unity. Thus,matching
was undertaken for dual and monotherapy patients with
propensities in the range 0.2 to unity. This led to us discarding
12 dual therapy patients without sufficiently close matches. A
total of 177monotherapy and 177 dual therapy patients (a total
of 354) were matched. There were 29 MACE events amongst
mono- and dual therapy patients in the study population as a
whole and 17 in the matched study group. Two DAPT and 10
monotherapy patients with MACE were discarded in the
matching process. There were 19 patients with bleeding
events in the two groups in the study population as a whole
and 17 in the matched population. Two DAPT and two mon-
otherapy patients with bleeding events were discarded in the
matching process. The clinical characteristics of the matched
patients are shown in Table 4. The incidence of MACE and
bleeding were compared in the matched single and DAPT
groups. Amongst the 177 propensity matched patients who
remained on DAPT, there were 11 MACE events, compared
with six in the group on monotherapy. There was no statisti-
cally significant difference in the incidence of MACE between
the two groups [RR 1.83 (0.69e4.85), P¼0.32]. The incidence of
clinically important bleeding was significantly greater in the
dual therapy group than in the monotherapy group. There
were 12 bleeding events in the 177 propensity matched pa-
tients receiving DAPT as compared with three in the mono-
therapy group giving an RR of 4.00 (1.15e13.93), P¼0.031.Discussion
Current guidelines are based on the premise that DAPT offers
effective protection against perioperative MI in patients who
have undergone PCI undergoing noncardiac surgery. The 2014
European Society of Cardiology and ESA (ESC/ESA) joint
guidelines on noncardiac surgery recommend DAPT for at
least 1 month after PCI and BMS implantation, for 6 months
after the insertion of a new generation drug-eluting stent and
for 12 months after an acute coronary syndrome.23 The 2014
American College of Cardiology and American Heart Associa-
tion guidelines on perioperative cardiovascular evaluation
state that elective noncardiac surgery should not be under-
taken within 30 days of BMS implantation or 12 months of DES
implantation if DAPT will need to be discontinued.24
Wewere unable to demonstrate a protective effect of DAPT,
and the continuation of two antiplatelet agents appeared to beassociated with a risk of harm from clinically significant
bleeding. The results of OBTAIN are consistent a nested
caseecontrol study comparing 284 patients who had under-
gone noncardiac surgery between 6 weeks and 2 yr after PCI,
showing no association between the cessation of all anti-
platelet therapy and major postoperative cardiac events.25
Four earlier studies also found no reduction in perioperative
MACE in patients who remained on DAPT.20,21,26 In contrast,
the RECO study, an observational study of 1134 patients who
underwent noncardiac surgery after PCI,27 showed no associ-
ation between complete antiplatelet therapy interruption for
>5 days and perioperative cerebrovascular or cardiovascular
events.
Twenty-two patients in OBTAIN suffered major bleeding
events, and 14 of these received DAPT in the perioperative
period, supportive for an association between perioperative
bleeding and DAPT in patients undergoing cardiac surgery.13,28
In the TRITON-TIMI38 trial, prasugrel was found to be associ-
ated with a 13.4% incidence of major bleeding in patients who
underwent coronary artery bypass graft procedures compared
with 3.2% in patients who were not taking this drug.29 The
evidence for an association between bleeding and DAPT in
noncardiac surgery is less clear. A study of 520 patients who
underwent noncardiac surgery after PCI reported no associa-
tion between antiplatelet agent use and transfusion.21 Simi-
larly, the RECO study found no association between
perioperative antiplatelet therapy and bleeding.27 The results
of OBTAIN stand in contrast to these studies, and add sub-
stantially to the data suggesting a perioperative risk of
bleeding associated with DAPT.
The Perioperative Ischaemic Evaluation-2 (POISE-2) study
did not demonstrate a protective effect of perioperative aspirin
in patients at risk of vascular complications after surgery.30
OBTAIN did not show a difference between the incidence of
MACE between patients taking DAPT and those on aspirin
alone, while perioperative myocardial injury is associated
with worse long-term outcome.31 Moreover, the incidence of
MACE was almost similar in patients who discontinued all
antiplatelet therapy and patients who continued single anti-
platelet therapy. In view of the increased incidence of bleeding
in the DAPT group, OBTAIN therefore suggests that perioper-
ative continuation of DAPT may harm some patients rather
than protecting them from perioperative cardiac events. The
failure of DAPT to offer protection from perioperative
myocardial injury may reflect differing mechanisms of peri-
operative myocardial injury and non-operative MI, which was
demonstrated in a study using optical coherence tomography
in patients with MI during surgery.32
OBTAIN included patientswhohad undergone PCI up to 4 yr
before surgery.Whilst current guidelines recommendDAPT for
up to a year after PCI, late in-stent thrombosis has been
Table 4 Table showing balance between the characteristics of the matched groups receiving mono and dual antiplatelet therapy.
(Some percentages do not add up to precisely 100% because of rounding.) It has been suggested that standardised differences of <0.1 or
<0.25 represent acceptable matching.4243 CVA, cerebrovascular accident; MI, myocardial infarction; PCI percutaneous coronary
intervention
Factor Monotherapy, n (%) Dual-therapy, n (%) Standardised difference
Subjects (number) 177 177
Sex Male 136 (76.8) 145 (81.9) 0.126
Female 41 (23.3) 32 (18.1)
Age (yr) 31e59 32 (18.1) 38 (21.5) 0.085
60e69 56 (31.6) 59 (33.3) 0.036
70e79 66 (37.3) 59 (33.3) 0.083
80e91 23 (13.0) 21 (11.9) 0.034
Country group <25% 85 (48.0) 77 (43.5) 0.091
25e50% 72 (40.7) 70 (39.5) 0.023
>50% 20 (11.3) 30 (16.9) 0.163
Smoking Never 61 (34.5) 63 (35.6) 0.024
Ex-smoker 89 (50.3) 84 (47.5) 0.057
Current 27 (15.3) 30 (16.9) 0.046
Able to climb stairs Able 128 (72.3) 117 (66.1) 0.135
Unable 35 (19.8) 38 (21.5) 0.042
Not recorded 14 (7.9) 22 (12.4) 0.150
Diabetes mellitus Diabetic 37 (20.9) 51 (28.8) 0.184
Non-diabetic 140 (79.1) 126 (71.2)
Urgency of PCI Elective 102 (57.6) 114 (64.4) 0.139
Acute 75 (42.4) 63 (35.6)
Days from PCI to surgery 440 (237e582) 310 (141e532) 0.15
No. of stents 0 or1 98 (55.4) 94 (53.1) 0.045
2þ 79 (44.6) 83 (46.9)
Ejection fraction Impaired 34 (19.2) 42 (23.7) 0.139
Good or not recorded 143 (80.8) 135 (76.3)
Urgency of surgery Elective 171 (96.6) 171 (96.6) 0.0
Acute 6 (3.4) 6 (3.4)
Operation risk Low 79 (44.6) 79 (44.6) 0.000
Intermediate 93 (52.5) 83 (46.9) 0.113
High 5 (2.8) 15 (8.5) 0.247
ASA physcial status 1 or 2 46 (26.0) 42 (23.7) 0.052
3 113 (63.8) 104 (58.8) 0.105
4 18 (10.2) 31 (17.5) 0.214
Previous MI Previous MI 65 (36.7) 67 (37.9) 0.023
No previous MI 112 (63.3) 110 (62.1)
Current Angina Angina 80 (45.2) 82 (46.3) 0.023
No angina 97 (54.8) 95 (53.7)
History of heart failure Heart failure 7 (4.0) 12 (6.8) 0.126
No heart failure 170 (96.0) 165 (93.2)
Previous CVA Previous CVA 5 (2.8) 17 (9.6) 0.284
No previous CVA 172 (97.2) 160 (90.4)
176 - Howell et al.reported up to as late as 5.5 yr after PCI and the risk of in-stent
thrombosis in non-surgical patients has been a cause of
considerable concern.8,9,33e36 A recent meta-analysis indeed
showed that continuation of DAPT for 18e48 months after PCI
was associated with a decreased incidence of stent thrombosis
andMI, but with an increased risk of major bleeding.37 Overall,
there was weak evidence of increased mortality with pro-
longed DAPT. Nevertheless, DAPT beyond 1 yr after PCImay be
of benefit in patients at higher risk of in-stent thrombosis.
Based on the results of the PEGASUS study, the UK National
Institute for Health and Care Excellence now recommends
ticagrelor at reduced dose (60 mg bd) for up to 3 yr after the
usual 12months course in selected patientswith recentMI.38,39
In OBTAIN, patients were more likely to continue DAPT
through the perioperative period if they underwent surgery in
the 12 months immediately after PCI. However, there were too
few MACE or bleeding events to allow an adequately powered
examination of the interaction between the effect ofcontinuing DAPT through the perioperative period and the
interval between PCI and surgery.
Our study suggests a significant variation in the manage-
ment of DAPT between countries. Patients from southern and
eastern Europewhowere included in OBTAINweremore likely
to receive DAPT through the perioperative period, without
particular reasons for this strategy. The international long-
term observational study of acute coronary syndrome (EPI-
COR) also identified national variations in the continuation of
DAPT beyond 12 months after the index cardiac event.40
Country was a key determinant for the continuation of DAPT
at 12 months beyond acute coronary syndrome in EPICOR, but
whether this is because of cultural, economic, or organisa-
tional reasons remains unclear and requires further study.
Moreover, there was no evidence of any difference in outcome
between different participating countries.
Our power calculation suggested that approximately 980 pa-
tients should be recruited. However, the study was terminated
Perioperative antiplatelet therapy after PCI - 177early as the data showed a clinically important association be-
tweenDAPTandbleedingwhilst suggestinganeffect forMACE in
the opposite direction to that expected (i.e. a greater incidence of
MACE in theDAPTgroup) that could not be confirmedwithin the
planned sample size. The power of the current study to confirm
such a difference was calculated to be between 0.45 and 0.5,
requiring the inclusion of 1700 patients to have an 80% power to
confirm this difference, with the same proportion of patients
remainingonDAPT.Aprospective randomisedcontrolled trial in
which mono antiplatelet therapy (MAPT) and DAPT groups are
equally matched would require approximately 1630 patients to
have an 80% power to confirm this finding.
A limitation of OBTAIN is the absence of formal surveil-
lance for perioperative MACE and cardiac troponin concen-
trations. The VISION study demonstrated that such events do
have long-term prognostic implications, although the optimal
management of a patient who has suffered a perioperative
troponin increase remains unclear.31
Comparing the characteristics of the 354 matched patients
(Table 4) with those of the 761 mono and dual therapy patients
in the population as a whole suggests that the matched pop-
ulation is representative of the wider population. For most
characteristics, the proportion of patients in the matched
group was within 5% of that in the population as a whole. The
proportion of patients with a history of previous MI was 30.4%
in the monotherapy group in the population as a whole, but
36.7% in the monotherapy group in the matched population.
There was also some difference in the distribution of ASA
scores. Eighteen patients without ASA data were excluded
from the matched analysis. In the monotherapy group, there
were more ASA 1 and 2 patients amongst the monotherapy
patients in the population as a whole than in the matched
patients (31.7% vs 23.7%). For the dual therapy patients, there
were more ASA 4 patients in the dual therapy group in the
population as a whole (16.4% vs 8.5%). There was a difference
in the history of stroke between the two groups in the popu-
lation as awhole (monotherapy 5.5% vs dual therapy 9.3%) that
was more marked the matched group (2.8% vs 9.6%). In the
population as a whole, the monotherapy group included 66%
of patients from countries where more than 75% of patients
had DAPT discontinued. This compared with 40.4% in the dual
therapy group. As might be expected, the matching process
improved the balance between these two characteristics.
There is no absolute standard for assessing balance between
propensity matched groups. Harder and colleagues41 suggest a
standardised mean difference of 0.25 as a ‘rule of thumb’ for
balance between covariates whilst noting that others have
suggested stricter cut-offs. Thepropensitymatchedmodel used
inouranalysis achievedstandardisedmeandifferencesof<0.25
in all but one measured covariate (CVA). The analysis was
limited by the sample size andsomecovariatesdidnotmeet the
stricter matching criteria of a standardised mean difference of
0.1 suggested by Austin and colleagues.42 However, the pro-
pensity matching process met the standard of model of
achieving acceptable balance with an standardized mean dif-
ference (SMD) of <0.25 for those covariates of most importance
to the outcomes of interest.41 A frequent criticism of 1:1 pro-
pensity matching is that it leads to the discarding of a large
number of observations and so reduces statistical power. This
has been challenged on the basis that if the greater loss of
subjects is from one group, then the loss of power may not be
great and is offset by the advantages of comparing groups that
aremore similar.43 Thematching process reduced to about 20%
the power of the study to confirm the significance of theobserved difference in the incidence of MACE in MAPT and
DAPT patients. As noted above, a substantially larger study
would have been required to confirm this observation.
It is possible that there are unobserved characteristics of
the patients that have influenced the findings. The fact that
information on the type of stent or PCI urgency level was often
not available reflects the difficulty of garnering these data
retrospectively. However, OBTAIN supports the discussion
that the continuation of DAPT in patients undergoing PCI
requiring noncardiac surgery is a difficult one, and that it is
unsure whether protection from perioperative MACE out-
weighs the risk for bleeding.OBTAIN collaborators
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